Description: PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs; energy drinks, ready-to-drink healthy beverage products, supplements, and other preventive products; nutritional products comprising powdered milk products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs; and non-milk nutritional products. In addition, the company operates Mitrasana Clinics, a health care service, contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; operates as an agent for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was founded in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe Farma Tbk. is a subsidiary of PT Gira Sole Prima.
Home Page: www.kalbe.co.id
Gedung KALBE
Jakarta,
10510
Indonesia
Phone:
62 21 4287 3888
Officers
| Name | Title |
|---|---|
| Mr. - Vidjongtius | Pres Director |
| Mr. Lukito Kurniawan Gozali | Head of Investor Relations |
| Ms. Lanny Soputro | Director of HR, Gen. Affairs & HSSE |
| Mr. Kurniawan Suhartono | Head of Internal Audit Unit |
| Mr. Sie Djohan | Director of Corp. Bus. Devel., Management System & Regulatory Affairs and Director |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 24.0385 |
|---|---|
| Trailing PE: | 28.2796 |
| Price-to-Book MRQ: | 4.748 |
| Price-to-Sales TTM: | 3.2793 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12644 |